IFRS earnings per share growth vs Novel active substance launches

IFRS earnings per share growth and Novel active substance launches worldwide, compared over time.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

IFRS earnings per share growth

Unit: % · 2 observations

Line chart
IFRS earnings per share growthIFRS earnings per share growth. 2 observations from Q1 2026 to Q2 2026, ranging from -91% to -65.6%. Latest value -91% (Q2 2026). % -100 -80 -60 -40 -20 0 2004 2008 2012 2016 2020 2024 -66% -91%
IFRS earnings per share growthIFRS earnings per share growth. 2 observations from Q1 2026 to Q2 2026, ranging from -91% to -65.6%. Latest value -91% (Q2 2026). % -120 -90 -60 -30 0 2004 2008 2012 2016 2020 2024 -66% -91%
IFRS earnings per share growthIFRS earnings per share growth. 2 observations from Q1 2026 to Q2 2026, ranging from -91% to -65.6%. Latest value -91% (Q2 2026). % -120 -90 -60 -30 0 2004 2008 2012 2016 2020 2024 -66% -91%
View the underlying data
IFRS earnings per share growth
Period Type Value
Q1 2026 Actual -65.6%
Q2 2026 Actual -91%
Source: Sanofi · CC BY 4.0 · Full series

Novel active substance launches

Unit: count · 2 observations

Line chart
Novel active substance launchesNovel active substance launches. 2 observations from 2004–2023 to 2025, ranging from 79 to 942. Latest value 79 (2025). 0 200 400 600 800 1,000 2004 2008 2012 2016 2020 2024 942 79
Novel active substance launchesNovel active substance launches. 2 observations from 2004–2023 to 2025, ranging from 79 to 942. Latest value 79 (2025). 0 300 600 900 1,200 2004 2008 2012 2016 2020 2024 942 79
Novel active substance launchesNovel active substance launches. 2 observations from 2004–2023 to 2025, ranging from 79 to 942. Latest value 79 (2025). 0 300 600 900 1,200 2004 2008 2012 2016 2020 2024 942 79
View the underlying data
Novel active substance launches
Period Type Value
2004–2023 Actual 942
2025 Actual 79
Source: IFPMA, IQVIA · CC BY 4.0 · Full series

Provenance

Where these numbers come from

IFRS earnings per share growth

Percentage change in IFRS earnings per share compared to the prior-year period.

2 observations in Global · source organisations: Sanofi

Novel active substance launches

Total number of novel active substances launched.

2 observations in Global · source organisations: IFPMA, IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related